Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15712180 | 0.94 | OPRK1 (0.47) | OPRK1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL15712249 | 0.94 | OPRK1 (0.45) | OPRK1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL15712188 | 0.84 | POLB (0.36) | OPRK1LMNAPOLBSMN1; SMN2DHODH | |
| SCHEMBL17067782 | 0.83 | OPRK1 (0.47) | OPRK1LMNAPOLBSMN1; SMN2DHODH | |
| SCHEMBL14192002 | 0.82 | OPRK1 (0.47) | OPRK1LMNAPOLBSMN1; SMN2DHODH | |
| SCHEMBL17060339 | 0.82 | OPRK1 (0.47) | OPRK1LMNAPOLBSMN1; SMN2DHODH | |
| SCHEMBL15712179 | 0.81 | OPRK1 (0.36) | OPRK1LMNAPOLBSMN1; SMN2ABL1 | |
| SCHEMBL3727102 | 0.81 | DHODH (0.46) | LMNASMN1; SMN2DHODH | |
| SCHEMBL2357625 | 0.78 | ABL1 (0.47) | OPRK1POLBABL1MAPT | |
| SCHEMBL473981 | 0.77 | OPRK1 (0.48) | OPRK1SMN1; SMN2SLC6A3ABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4190402-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORP (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-112689633-B | For inhibiting Nav1.8 Pyridinecarboxamide Compounds | 利伯研究所公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4190402-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM Corporation (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-116056766-A | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | 富士胶片株式会社 | 2023-05-02 | — | — | CN | disclosed |
| WO-2014069510-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-05-08 | — | — | WO | disclosed |
| US-8691852-B2 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors | AMIRALL, S.A. (ES) | 2014-04-08 | — | — | US | disclosed |
| US-20120294854-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. | 2012-11-22 | — | — | US | disclosed |
| US-8258308-B2 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| EP-2121614-B1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2012-06-20 | — | — | EP | disclosed |
| CN-101589025-B | Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors | ALMIRALL LAB | 2012-05-30 | — | — | CN | disclosed |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| EP-2121614-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | disclosed |
| CN-101589025-A | Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors | ALMIRALL LAB (ES) | 2009-11-25 | — | — | CN | disclosed |
| WO-2008077639-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | DHRS9, DHODH, CBR1 | OPRK1 4203/4885LMNA 4322/4885POLB 3411/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | OPRK1 760/4885LMNA 1580/4885POLB 4293/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | OPRK1 257/4885LMNA 916/4885POLB 4485/4885 |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, NQO2, DAO | OPRK1 1256/4885LMNA 4082/4885POLB 2182/4885 |
| US-20120294854-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, NQO2, DAO | OPRK1 1256/4885LMNA 4082/4885POLB 2182/4885 |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | CBR1, DHODH, CBR3 | OPRK1 2720/4885LMNA 3287/4885POLB 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.